TRIM41-Mediated Ubiquitination of Nucleoprotein Limits Vesicular Stomatitis Virus Infection.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
22 01 2020
Historique:
received: 22 11 2019
revised: 17 01 2020
accepted: 20 01 2020
entrez: 26 1 2020
pubmed: 26 1 2020
medline: 20 2 2021
Statut: epublish

Résumé

Vesicular stomatitis virus (VSV) is a zoonotic, negative-stranded RNA virus of the family Rhabdoviridae. The nucleoprotein (N) of VSV protects the viral genomic RNA and plays an essential role in viral transcription and replication, which makes the nucleoprotein an ideal target of host defense. However, whether and how host innate/intrinsic immunity limits VSV infection by targeting the N protein are unknown. In this study, we found that the N protein of VSV (VSV-N) interacted with a ubiquitin E3 ligase, tripartite motif protein 41 (TRIM41). Overexpression of TRIM41 inhibited VSV infection. Conversely, the depletion of TRIM41 increased host susceptibility to VSV. Furthermore, the E3 ligase defective mutant of TRIM41 failed to limit VSV infection, suggesting the requirement of the E3 ligase activity of TRIM41 in viral restriction. Indeed, TRIM41 ubiquitinated VSV-N in cells and in vitro. TRIM41-mediated ubiquitination leads to the degradation of VSV-N through proteasome, thereby limiting VSV infection. Taken together, our study identifies TRIM41 as a new intrinsic immune factor against VSV by targeting the viral nucleoprotein for ubiquitination and subsequent protein degradation.

Identifiants

pubmed: 31979016
pii: v12020131
doi: 10.3390/v12020131
pmc: PMC7077221
pii:
doi:

Substances chimiques

Nucleocapsid Proteins 0
TRIM41 protein, human EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27
Proteasome Endopeptidase Complex EC 3.4.25.1

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R15 AI126360
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI137750
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103648
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI141399
Pays : United States

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Future Virol. 2019 Feb;14(2):107-122
pubmed: 31406497
Cell Mol Immunol. 2016 Jan;13(1):94-102
pubmed: 25683609
J Interferon Cytokine Res. 2011 Jan;31(1):145-58
pubmed: 21198351
PLoS Pathog. 2015 Jun 09;11(6):e1004960
pubmed: 26057645
J Virol. 2011 Apr;85(8):3733-45
pubmed: 21289118
Virus Res. 2007 Nov;129(2):246-51
pubmed: 17764775
J Virol. 2018 Jul 31;92(16):
pubmed: 29899090
Immunol Rev. 2009 Jan;227(1):75-86
pubmed: 19120477
J Interferon Cytokine Res. 2009 Sep;29(9):499-509
pubmed: 19715459
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
PLoS Pathog. 2014 Feb 27;10(2):e1003975
pubmed: 24586174
Virol J. 2007 Jul 10;4:72
pubmed: 17623082
PLoS One. 2013 Aug 01;8(8):e70001
pubmed: 23936368
Hepatology. 2009 Aug;50(2):424-33
pubmed: 19585648
Nature. 2007 Apr 19;446(7138):916-920
pubmed: 17392790
Front Microbiol. 2016 Dec 19;7:2027
pubmed: 28066353
J Virol. 1998 Feb;72(2):1043-51
pubmed: 9444998
Cell. 2010 Mar 19;140(6):805-20
pubmed: 20303872
J Virol. 2002 Apr;76(8):3810-8
pubmed: 11907221
Nat Commun. 2017 Feb 07;8:13876
pubmed: 28169297
J Gen Virol. 2009 Mar;90(Pt 3):536-545
pubmed: 19218198
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):233-8
pubmed: 14679297
Curr Opin Immunol. 2010 Feb;22(1):41-7
pubmed: 20061127
Cell Biosci. 2018 May 9;8:35
pubmed: 29760876
Cell Mol Life Sci. 2008 Jan;65(2):282-94
pubmed: 17938861
Science. 2003 May 16;300(5622):1148-51
pubmed: 12702806
Cell Rep. 2016 Aug 2;16(5):1315-1325
pubmed: 27425606
Sci Rep. 2016 Aug 31;6:32336
pubmed: 27578425
Nature. 2011 Apr 21;472(7343):361-5
pubmed: 21512573
Biosci Rep. 2007 Oct;27(4-5):275-98
pubmed: 17610154
J Virol. 2013 Apr;87(8):4523-33
pubmed: 23408607
Curr Top Microbiol Immunol. 2005;292:1-24
pubmed: 15981465
Int J Mol Sci. 2017 Aug 01;18(8):
pubmed: 28763020
PLoS One. 2016 Nov 3;11(11):e0165420
pubmed: 27812135
J Exp Med. 2004 Jun 21;199(12):1641-50
pubmed: 15210742
Nat Immunol. 2003 May;4(5):491-6
pubmed: 12692549
Sci Rep. 2016 Sep 26;6:33698
pubmed: 27667714
J Virol. 2014 Dec;88(23):13821-35
pubmed: 25253338

Auteurs

Girish Patil (G)

Department of Physiological Sciences, Center for Veterinary Health Sciences, Oklahoma State University, 156 McElroy Hall, Stillwater, OK 74078, USA.

Lingling Xu (L)

Department of Physiological Sciences, Center for Veterinary Health Sciences, Oklahoma State University, 156 McElroy Hall, Stillwater, OK 74078, USA.

Yakun Wu (Y)

Department of Microbiology and Immunology, Tulane University, New Orleans, LA 70112, USA.

Kun Song (K)

Department of Microbiology and Immunology, Tulane University, New Orleans, LA 70112, USA.

Wenzhuo Hao (W)

Department of Microbiology and Immunology, Tulane University, New Orleans, LA 70112, USA.

Fang Hua (F)

Department of Microbiology and Immunology, Tulane University, New Orleans, LA 70112, USA.

Lingyan Wang (L)

Department of Microbiology and Immunology, Tulane University, New Orleans, LA 70112, USA.

Shitao Li (S)

Department of Physiological Sciences, Center for Veterinary Health Sciences, Oklahoma State University, 156 McElroy Hall, Stillwater, OK 74078, USA.
Department of Microbiology and Immunology, Tulane University, New Orleans, LA 70112, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH